1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsEnterprise Innovation Catalyst Fund (EI Catalyst Fund) is sponsored by Weill Cornell Medicine. Accelerates translational research projects into innovative healthcare solutions, facilitating commercialization and partnerships.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Enterprise Innovation Catalyst Fund (EI Catalyst Fund) | Enterprise Innovation Enterprise Innovation Catalyst Fund (EI Catalyst Fund) The EI Catalyst Fund, launched in the spring of 2025, will build on the success of the Daedalus Fund for Innovation and provide funds to bridge critical gaps for Weill Cornell Medicine innovations but with an expanded remit that covers multiple asset pillars at different development stages, facilitates the use of expert consultants and provides educational programming for Weill Cornell innovators.
The purpose of the EI Catalyst Fund is to accelerate and transform translational research projects into innovative healthcare solutions to significantly improve patient care. The funds will move these projects toward commercialization by adding value and creating more "partnership ready" opportunities through the achievement of one or more value-creation inflection points.
The fund supports proof of concept of technologies to reach the next inflection point and attract interests from industry partners, entrepreneurs and investors to 1) license technologies for commercialization, 2) create new ventures, or 3) establish corporate research collaboration.
The EI Catalyst Fund will introduce two new programs and house two pre-existing de-risking programs, all of which will be organized into three discrete tiers. Proto Stage Award will fund device and digital health projects and other early-stage projects on a rolling basis to validate preliminary proof-of-concept ideas and expedite the development of prototypes for commercial advancement.
*The application process is now open for the Proto Stage Awards. See details here . Validation Stage Award , incorporating the Selma and Lawrence Ruben Validation Stage Awards, will benefit projects that have already demonstrated preliminary proof of concept, identified unmet need in the market and developed a plan for commercialization.
This award will serve as a reimagining of the Daedalus Fund for Innovation, which was established in 2014, to support early-stage applied and translational research projects that have clear, near-term commercial potential. *The application process is now open for the Validation Stage Award.
There are two stages to the application process (see attached PDF) , short pre-proposals which will be reviewed and selected projects invited to submit a more detailed full proposal. Breakout Stage Award will allow Enterprise Innovation to provide larger funding awards to projects that require specific commercial de-risking experiments necessary for the project to advance to partnership.
Enterprise Innovation will leverage external industry and investment advisors to provide feedback on project design for programs that have previously received encouraging commercial feedback following active marketing by Enterprise Innovation as well as outsource certain tasks to meet industry requirements. Enterprise Innovation will facilitate proposal submission and review processes for all three funding tiers.
Collaboration Opportunities Cornell University Center for Technology Licensing Weill Cornell Medicine Enterprise Innovation Email: enterpriseinnovation@med. cornell. edu
According to the current listing, eligibility includes: Universities, including UC Davis College of Letters and Science. Confirm the full requirements in the official notice before applying.
Enterprise Innovation Catalyst Fund (EI Catalyst Fund) is funded by Weill Cornell Medicine. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
DARPA pre-released Release 6 of its FY26 SBIR BAA on September 2, 2026. Five of the seven SBIR topics belong to the Biological Technologies Office, and four of those describe one continuous problem: keeping a casualty alive with no surgeon, no imaging, and no evacuation. Here are the award sizes, the Direct-to-Phase-II gates, and the sequencing DARPA is buying.
Read articleThe NIH Common Fund launched PRIMED-AI — Precision Medicine with AI: Integrating Imaging with Multimodal Data — as five coordinated funding opportunities (RFA-RM-27-011 through -015) that build a full pipeline from standards to clinic. Here is how the Playbook, Data-to-Model partnerships, Model-to-Clinic translation, Validation Center, and Logistics Center fit together, what each pays, who is eligible, and how to position before the October 2026 deadlines.
Read articleUSDA's FY2026 GusNIP Produce Prescription Program will make roughly 12 awards of up to $500,000 over three years — with no matching requirement — to nonprofits and government agencies that partner with healthcare providers to prescribe fresh fruits and vegetables. Here is who is eligible, why the mandatory clinical partner is the whole game, how the evidence base got strong enough to matter, and how to build a July 16 application.
Read article